logo
Sign in

AMERICAN GENE TECHNOLOGIES INTERNATIONAL

ROCKVILLE, MD · Biotech · Private

Lentiviral vector-based gene and cell therapies

Claim this profile

Follows are private to you and power your alerts

Updated · americangene.com

Sector
Biotech
Headquarters
ROCKVILLE, MD
Latest Form D
$10M offered, Nov 2025
Total capital
$3.2M
Federal grants
$232K
1 award · 2015
Rank in peer group#241 of 392
Private capital raised
$2.8M
4 Form D · last Nov 2025
11 months since last filing
Federal contracts
$150K
1 award · Health and Human S
Rank in Biotech#305 of 4373
Granted patents
23
17 pending · first 2021
Rank in peer group#4 of 392

Capital timeline

2012201420162018202020222024FEDERAL ↑EQUITY ↓Cumulative $13.2M$150K$232K1st Form D$1.3M3rd Form D$1.2M4th Form D$10M
2012201620202024FEDERAL ↑EQUITY ↓Cumulative $13.2M$150K$232K3rd Form D$1.2M4th Form D$10M

Latest events

  • Offering registeredForm D · SEC · 4th filing$10M
  • Private capital raisedForm D · SEC · 3rd filing$1.2M
  • Federal grantHealth and Human S · Phase I · Generation and Treatment of a Mouse Eye Model for Familial Dysautonomia$232K
  • Private capital raisedForm D · SEC · 2nd filing$341K
  • Private capital raisedForm D · SEC · 1st filing$1.3M
  • Federal contractHealth and Human S · Igf::ot::igf Other Functions: Treatment Of Hiv/aids In Idus By Therapeutic Lentivirus$150K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

14months

from AMERICAN GENE TECHNOLOGIES INTERNATIONAL’s first federal award to its first private round.

First federal award · Jul 2012
Health and Human S · $150K
First Form D · Sep 2013
$1.3M · 1st Form D
Awards before first raise
1 award

An association in public records, not a cause or a prediction.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Granted patents#4 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Barry Haden WellsDirectorNamed in SEC Form D filings
  • Jeffrey GalvinExecutive Officer, DirectorNamed in SEC Form D filings
  • William Drew PalinExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 23 granted of 40
Show all 40 patent records

Related companies, and why

  • INTACT GENOMICS INCSimilar federal contract value in Biotech · $168K in contracts
  • REGIS TECHNOLOGIES INCSimilar federal contract value in Biotech · $160K in contracts
  • Scale BiosciencesSimilar federal contract value in Biotech · $151K in contracts
  • ALPHATHERASimilar federal contract value in Biotech · $150K in contracts
  • CYANVAC LLCSimilar federal contract value in Biotech · $150K in contracts
  • EVAS THERAPEUTICS LLCSimilar federal contract value in Biotech · $150K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .